利拉鲁肽对成人 2 型糖尿病患者 C 反应蛋白 (CRP) 的疗效和安全性:对对照试验进行GRADE评估的系统综述和剂量反应荟萃分析

IF 2.4 Q3 NUTRITION & DIETETICS PharmaNutrition Pub Date : 2024-09-18 DOI:10.1016/j.phanu.2024.100409
{"title":"利拉鲁肽对成人 2 型糖尿病患者 C 反应蛋白 (CRP) 的疗效和安全性:对对照试验进行GRADE评估的系统综述和剂量反应荟萃分析","authors":"","doi":"10.1016/j.phanu.2024.100409","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Liraglutide (LRG) is an analog of glucagon-like-peptide-1 which has beneficial effects on controlling glycemic in diabetes patients. However, the effect of liraglutide on the C-reactive protein (CRP) was controversial in different studies. So, this study aimed to investigate the effect of LRG on CRP in adults with type 2 diabetes (T2DM).</p></div><div><h3>Methods</h3><p>Through March 2024, Web of Science, PubMed, and Scopus electronic databases were searched for pertinent studies. Calculation of 95 % confidence intervals (CIs) and mean differences was done using random effects model. Standard methods assessed dose-response, meta-regression, sensitivity, and publication bias. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to calculate evidence certainty.</p></div><div><h3>Results</h3><p>Finally, after reviewing 9 eligible studies with 10 arms including 1494 participants, a significant decrease in CRP levels was observed after treatment with LRG (WMD = −0.692 mg/L, 95 % CI: −1.01, −0.37, P&lt;0.001). According to the results of the subgroup, LRG had greater effects in obese patients (Body mass index ≥30), high-quality studies, dosages &gt;1.6 mg/d and durations ≥24 weeks. Linear (P&lt;0.001) and non-linear (P <sub>dose-response</sub> =0.009) dose-response associations were observed between LRG dosages and CRP levels. According to the GRADE, evidence for CRP was high.</p></div><div><h3>Conclusions</h3><p>LRG had beneficial effects on CRP levels in adults with T2DM, especially in obese patients.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled trials\",\"authors\":\"\",\"doi\":\"10.1016/j.phanu.2024.100409\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Liraglutide (LRG) is an analog of glucagon-like-peptide-1 which has beneficial effects on controlling glycemic in diabetes patients. However, the effect of liraglutide on the C-reactive protein (CRP) was controversial in different studies. So, this study aimed to investigate the effect of LRG on CRP in adults with type 2 diabetes (T2DM).</p></div><div><h3>Methods</h3><p>Through March 2024, Web of Science, PubMed, and Scopus electronic databases were searched for pertinent studies. Calculation of 95 % confidence intervals (CIs) and mean differences was done using random effects model. Standard methods assessed dose-response, meta-regression, sensitivity, and publication bias. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to calculate evidence certainty.</p></div><div><h3>Results</h3><p>Finally, after reviewing 9 eligible studies with 10 arms including 1494 participants, a significant decrease in CRP levels was observed after treatment with LRG (WMD = −0.692 mg/L, 95 % CI: −1.01, −0.37, P&lt;0.001). According to the results of the subgroup, LRG had greater effects in obese patients (Body mass index ≥30), high-quality studies, dosages &gt;1.6 mg/d and durations ≥24 weeks. Linear (P&lt;0.001) and non-linear (P <sub>dose-response</sub> =0.009) dose-response associations were observed between LRG dosages and CRP levels. According to the GRADE, evidence for CRP was high.</p></div><div><h3>Conclusions</h3><p>LRG had beneficial effects on CRP levels in adults with T2DM, especially in obese patients.</p></div>\",\"PeriodicalId\":20049,\"journal\":{\"name\":\"PharmaNutrition\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmaNutrition\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213434424000355\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmaNutrition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213434424000355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

摘要

背景利拉鲁肽(LRG)是胰高血糖素样肽-1的类似物,对控制糖尿病患者的血糖有好处。然而,不同研究对利拉鲁肽对C反应蛋白(CRP)的影响存在争议。因此,本研究旨在探讨利拉鲁肽对成人 2 型糖尿病(T2DM)患者 CRP 的影响。方法截至 2024 年 3 月,在 Web of Science、PubMed 和 Scopus 电子数据库中检索了相关研究。使用随机效应模型计算95%置信区间(CI)和平均差异。采用标准方法评估剂量反应、元回归、敏感性和发表偏倚。结果最终,在回顾了9项符合条件的研究,共10个研究臂,包括1494名参与者后,观察到LRG治疗后CRP水平显著下降(WMD = -0.692 mg/L,95 % CI:-1.01,-0.37,P<0.001)。根据亚组结果,LRG对肥胖患者(体重指数≥30)、高质量研究、剂量>1.6 mg/d、持续时间≥24周的疗效更好。LRG剂量与CRP水平之间存在线性(P<0.001)和非线性(P剂量-反应=0.009)剂量-反应关系。结论LRG对患有T2DM的成人,尤其是肥胖患者的CRP水平有益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled trials

Background

Liraglutide (LRG) is an analog of glucagon-like-peptide-1 which has beneficial effects on controlling glycemic in diabetes patients. However, the effect of liraglutide on the C-reactive protein (CRP) was controversial in different studies. So, this study aimed to investigate the effect of LRG on CRP in adults with type 2 diabetes (T2DM).

Methods

Through March 2024, Web of Science, PubMed, and Scopus electronic databases were searched for pertinent studies. Calculation of 95 % confidence intervals (CIs) and mean differences was done using random effects model. Standard methods assessed dose-response, meta-regression, sensitivity, and publication bias. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to calculate evidence certainty.

Results

Finally, after reviewing 9 eligible studies with 10 arms including 1494 participants, a significant decrease in CRP levels was observed after treatment with LRG (WMD = −0.692 mg/L, 95 % CI: −1.01, −0.37, P<0.001). According to the results of the subgroup, LRG had greater effects in obese patients (Body mass index ≥30), high-quality studies, dosages >1.6 mg/d and durations ≥24 weeks. Linear (P<0.001) and non-linear (P dose-response =0.009) dose-response associations were observed between LRG dosages and CRP levels. According to the GRADE, evidence for CRP was high.

Conclusions

LRG had beneficial effects on CRP levels in adults with T2DM, especially in obese patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
PharmaNutrition
PharmaNutrition Agricultural and Biological Sciences-Food Science
CiteScore
5.70
自引率
3.10%
发文量
33
审稿时长
12 days
期刊最新文献
Advancements in psoriasis management: Integrating nutrient supplement with gut-brain-skin connection Can L-Methionine and S-Adenosyl-L-Methionine Effectively Mitigate Scopolamine-Induced Cognitive and Motor Deficits in Mice? Melatonin supplementation in preclinical colitis models: A systematic review and dose-response meta-analysis on inflammation, oxidative stress, and colon repair Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled trials Editorial Board
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1